When Will Retatrutide Be Available?

Retatrutide

28.7% weight loss

In the first Phase 3 TRIUMPH-4 trial, retatrutide's 12 mg dose produced 28.7% average body weight reduction over 68 weeks.

Eli Lilly, TRIUMPH-4 Topline Results, 2025

Eli Lilly, TRIUMPH-4 Topline Results, 2025

View as image

Retatrutide is the triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. The Phase 2 data showed up to 24.2% body weight reduction.^[1] The first Phase 3 result, from TRIUMPH-4, pushed that number to 28.7% at the highest dose. These are the largest weight loss numbers ever reported for any anti-obesity medication in clinical trials. So the question everyone is asking is straightforward: when can patients actually get it?

The realistic answer, based on Eli Lilly's clinical trial program and standard FDA review timelines: mid-2027 at the earliest. Seven additional Phase 3 trials are reporting results throughout 2026. If those trials succeed, Lilly is expected to submit a New Drug Application in late 2026. The FDA typically takes 6 to 10 months to review. That puts the earliest approval decision somewhere in the second or third quarter of 2027.

What the Phase 2 Data Showed

Two landmark Phase 2 trials established retatrutide's clinical profile. Jastreboff et al. (2023) published the obesity trial in the New England Journal of Medicine.^[1] The trial enrolled 338 adults with obesity or overweight and tested doses from 1 mg to 12 mg weekly over 48 weeks. At the highest dose (12 mg), participants lost an average of 24.2% of body weight. At the 8 mg dose, the average was 22.8%. Even the lowest tested dose (1 mg) produced meaningful weight loss.

Rosenstock et al. (2023) published the companion type 2 diabetes trial in The Lancet.^[2] In 281 participants with type 2 diabetes, retatrutide at 12 mg reduced HbA1c by 2.02 percentage points and body weight by 16.94% over 36 weeks. These results exceeded what semaglutide and tirzepatide achieved in their Phase 2 programs, and the comparison between all three drugs remains a central topic in metabolic pharmacology.

The weight loss curves in both trials had not plateaued by the end of the study period, suggesting that longer treatment at higher doses could produce even greater reductions. The Phase 3 TRIUMPH-4 result of 28.7% at 68 weeks confirmed that expectation.

The Phase 3 TRIUMPH Program

Eli Lilly designed the TRIUMPH program as a comprehensive Phase 3 evaluation spanning multiple conditions. As of early 2026, the program includes:

TRIUMPH-1: Obesity/overweight without diabetes. Primary outcome: percent change in body weight.

TRIUMPH-2: Type 2 diabetes. Primary outcome: HbA1c change.

TRIUMPH-3: Obesity/overweight with type 2 diabetes. Primary outcome: percent change in body weight.

TRIUMPH-4: Obesity with knee osteoarthritis. First Phase 3 to report results (December 2025). Showed 28.7% weight loss and 75% pain reduction at 12 mg over 68 weeks.

TRIUMPH-5: MASH (metabolic dysfunction-associated steatohepatitis). Building on the Phase 2 substudy that showed dramatic liver fat reduction.^[3]

TRIUMPH-6: Obstructive sleep apnea.

TRIUMPH-OC: Long-term cardiovascular outcomes trial.

The majority of these trials are projected to complete enrollment and primary endpoint data collection between Q2 and Q4 2026. This is the critical bottleneck for FDA submission. Lilly cannot file an NDA until the pivotal efficacy and safety data is compiled.

What the MASH Data Adds

Sanyal et al. (2024) published the Phase 2 MASH substudy in Nature Medicine, and the results were striking.^[3] Among participants with baseline liver fat of 10% or greater, retatrutide reduced liver fat dramatically across all doses. At the highest dose, 82.4% of participants achieved liver fat below the 5% threshold, essentially normalizing their liver fat content.

This finding expands retatrutide's potential market substantially. MASH affects an estimated 5-6% of the global adult population and has limited treatment options. If TRIUMPH-5 confirms the Phase 2 liver fat results, Lilly may pursue a separate indication for MASH, potentially filing for both obesity and liver disease approval.

Body Composition: The Glucagon Receptor Difference

One theoretical advantage of retatrutide over dual agonists like tirzepatide is the glucagon receptor component. Glucagon promotes fat oxidation and energy expenditure, which could shift the ratio of fat-to-lean mass loss toward fat.

Coskun et al. (2025) tested this in a body composition substudy of the Phase 2 diabetes trial.^[4] Using DEXA scanning, they found that retatrutide at 12 mg reduced total body fat mass by approximately 24% over 36 weeks. The ratio of fat mass lost to total weight lost was favorable compared to historical data from GLP-1 monotherapy trials, though direct head-to-head comparison with tirzepatide on body composition has not been conducted.

This matters for how retatrutide compares to existing drugs. If the glucagon component genuinely preserves lean mass while accelerating fat loss, it would address one of the most persistent criticisms of GLP-1 agonist therapy.

Safety Profile: What's Known So Far

The Phase 2 trials and early Phase 3 data identify a familiar but distinct side effect profile. A systematic review by Abdrabou Abouelmagd et al. (2025) pooled safety data across available retatrutide trials.^[5]

Gastrointestinal effects are the most common: nausea, diarrhea, vomiting, and decreased appetite. These are consistent with GLP-1 agonist class effects and generally diminish over time with dose escalation.

Dysesthesia is a new signal unique to retatrutide. In TRIUMPH-4, 20.9% of participants on the 12 mg dose reported skin sensitivity, tingling, or tenderness to the touch. This effect was not observed at similar rates in Phase 2 trials and may relate to the glucagon receptor component. Its clinical significance and long-term trajectory remain under investigation.

Heart rate increases of 2 to 4 beats per minute were observed, similar to other GLP-1 agonists.

Katsi et al. (2025) reviewed retatrutide's safety profile and concluded that the overall risk-benefit ratio appears favorable based on available data, while noting that long-term safety studies (the TRIUMPH-OC cardiovascular outcomes trial) are needed before drawing definitive conclusions.^[6]

The Realistic Timeline

Based on Lilly's clinical program and FDA regulatory norms, here is the most likely sequence:

Q2-Q4 2026: Remaining TRIUMPH trial results reported. This is where the program succeeds or encounters setbacks. If any pivotal trial fails to meet its primary endpoint, the timeline shifts.

Late 2026 or early 2027: NDA submission to the FDA. Lilly will need to compile manufacturing data, the complete safety database across all trials, and efficacy results into the application.

6-10 months after submission: FDA review. Standard review takes 10 months. Priority review (granted for drugs offering significant advantages over existing therapy) takes 6 months. Given retatrutide's efficacy profile, priority review is plausible.

Mid-to-late 2027: Earliest possible FDA approval decision. If granted, commercial launch could follow within months, though manufacturing scale-up and insurance coverage negotiations add additional time before widespread availability.

This timeline assumes no major safety signals emerge, no manufacturing issues arise, and the FDA does not request additional data. Each of these has derailed drug approvals in the past.

What Could Delay Availability

Several factors could push availability beyond 2027:

Trial delays. The TRIUMPH program spans thousands of participants across multiple countries. Enrollment delays, pandemic disruptions, or site closures could push completion timelines.

Safety signals. The dysesthesia finding in TRIUMPH-4 is being monitored. If it proves to be progressive or clinically significant in longer trials, the FDA may require additional safety data.

Manufacturing complexity. Retatrutide is a peptide requiring sophisticated manufacturing. Scaling production from clinical trial quantities to commercial supply takes time and investment. Tirzepatide's early supply shortages demonstrate this challenge.

FDA Advisory Committee. The FDA may convene an advisory committee meeting to review the data publicly before making an approval decision. This adds time but does not necessarily signal concern.

REMS requirements. If the FDA requires a Risk Evaluation and Mitigation Strategy (a formal safety management program), this adds complexity to the launch process.

What Retatrutide Means for the GLP-1 Landscape

Ganamurali and Sabarathinam (2026) described retatrutide as representing a "paradigm shift" in multi-hormonal pharmacotherapy.^[7] The triple agonist approach addresses three receptor systems simultaneously, theoretically maximizing weight loss while adding metabolic benefits from each receptor pathway.

If approved, retatrutide would enter a market that already includes semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro). Its competitive position depends on how the full Phase 3 data compares. The 28.7% weight loss in TRIUMPH-4 exceeds anything tirzepatide achieved in its SURMOUNT program (22.5% at the highest dose). But Phase 3 clinical trial results from the broader TRIUMPH program will determine whether that advantage holds across populations.

The MASH indication could be equally significant commercially. With semaglutide's Phase 3 MASH data (the ESSENCE trial) and retatrutide's Phase 2 liver fat results both showing strong effects, the liver disease market may become a major battleground between Novo Nordisk and Eli Lilly. Retatrutide's glucagon receptor activity provides a mechanistic advantage here: glucagon directly promotes hepatic fat oxidation, which may explain the 82.4% liver fat normalization rate observed in the Phase 2 substudy.^[3]

Practical Access After Approval

FDA approval does not guarantee immediate, widespread access. Several practical barriers exist between an approval decision and a patient receiving a prescription.

Insurance coverage. Payers will evaluate retatrutide's cost-effectiveness relative to semaglutide and tirzepatide. If priced at a premium, many insurance plans may require prior authorization, step therapy (trying cheaper alternatives first), or restrict coverage to patients meeting specific criteria. The experience with tirzepatide and semaglutide, where many patients faced coverage denials or high copays, will likely repeat.

Supply constraints. Peptide manufacturing at commercial scale is complex. Lilly has invested billions in manufacturing capacity, but the ramp from clinical trial quantities to serving millions of patients takes time. Tirzepatide experienced supply shortages for over a year after launch. Retatrutide will face the same scaling challenge.

Prescriber education. A new triple agonist with a unique side effect profile (particularly dysesthesia) will require physician education before widespread adoption. Early prescribing may concentrate among obesity medicine specialists and endocrinologists, with broader primary care adoption following.

Clinical trial enrollment. For patients who want access before FDA approval, enrollment in an active TRIUMPH trial remains the only legal pathway. ClinicalTrials.gov lists active recruitment sites for several ongoing studies.

The Bottom Line

Retatrutide has produced the largest weight loss results ever seen in obesity clinical trials: 28.7% at the highest dose in the first Phase 3 result. Seven additional Phase 3 trials are expected to report throughout 2026. If successful, Eli Lilly is projected to submit an NDA in late 2026, with an FDA decision possible by mid-to-late 2027. Manufacturing scale-up and insurance coverage will add additional time before widespread patient access.

Frequently Asked Questions

When will retatrutide be FDA approved?

Based on current trial timelines, the earliest possible FDA approval is mid-to-late 2027. Eli Lilly's TRIUMPH Phase 3 program is expected to report results throughout 2026, with NDA submission projected for late 2026. Standard FDA review takes 6 to 10 months. This timeline assumes no major trial setbacks or safety concerns.

How much weight can you lose on retatrutide?

In the Phase 2 obesity trial, participants on the 12 mg dose lost an average of 24.2% of body weight over 48 weeks (Jastreboff et al., 2023). The first Phase 3 result (TRIUMPH-4) showed 28.7% average weight loss at 12 mg over 68 weeks, equivalent to approximately 71.2 pounds. These are the largest weight loss results reported for any anti-obesity medication.

Is retatrutide better than semaglutide or tirzepatide?

Retatrutide's Phase 2 and early Phase 3 data show greater weight loss than either semaglutide (14.9% in STEP 1) or tirzepatide (22.5% in SURMOUNT-1). However, no head-to-head Phase 3 trial has compared all three drugs directly. The full TRIUMPH Phase 3 program will provide the data needed for more definitive comparisons across efficacy, safety, and tolerability.

What are retatrutide side effects?

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and decreased appetite. A new side effect called dysesthesia (skin tingling, sensitivity, or tenderness) was reported in 20.9% of participants on the highest dose in TRIUMPH-4. Heart rate increases of 2 to 4 beats per minute have also been observed. Long-term safety data from the TRIUMPH-OC cardiovascular outcomes trial is pending.

How is retatrutide different from tirzepatide?

Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors. Retatrutide is a triple agonist that adds glucagon receptor activation. The glucagon component is thought to increase energy expenditure and fat oxidation, potentially explaining retatrutide's greater weight loss. Coskun et al. (2025) found that retatrutide reduced body fat mass by 24% in a composition substudy, with a favorable fat-to-lean mass loss ratio.

Can you get retatrutide from a compounding pharmacy?

No. Retatrutide is an investigational drug that has not been approved by the FDA. It is not available through compounding pharmacies, online vendors, or any legal commercial channel. The only way to receive retatrutide currently is through enrollment in an active clinical trial. Products sold online claiming to be retatrutide are unregulated and of uncertain composition.